AI assistant
Aclaris Therapeutics, Inc. — Director's Dealing 2021
Apr 27, 2021
33670_dirs_2021-04-26_34c24fee-1dc3-4bc6-83e8-61e57791ab8a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-04-22
Reporting Person: Walker Neal (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-22 | Common Stock | S | 30000 | $26.8413 | Disposed | 1192427 | Direct |
Footnotes
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.